PAX-2 expression in non-neoplastic, primary neoplastic, and metastatic neoplastic tissue: A comprehensive immunohistochemical study

Applied Immunohistochemistry and Molecular Morphology

Volumn 18, Issue 4, 2010, Pages 323-332

  Zhai, Qihui Jim ^a   Ozcan, Ayhan ^a   Hamilton, Candice ^a   Shen, Steven S ^a   Coffey, Donna ^a   Krishnan, Bhuvaneswari ^b   Truong, Luan D ^a,b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

female genital tract; immunohistochemistry; metastasis; M llerian organ; neoplasm; PAX 2; renal cell carcinoma; transcription factor

Indexed keywords

TRANSCRIPTION FACTOR PAX2;

ARTICLE; BREAST CARCINOMA; COLON CARCINOMA; ENDOMETRIUM; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY ADENOMA; KIDNEY CARCINOMA; KIDNEY TUBULE CELL; LYMPHOCYTE; LYMPHOMA; MAJOR CLINICAL STUDY; METASTASIS; MIXED MULLERIAN TUMOR; OVARY CELL; PARATHYROID TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEMINAL VESICLE; UTERINE ENDOCERVIX; UTERINE TUBE;

CARCINOMA, RENAL CELL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY NEOPLASMS; PAX2 TRANSCRIPTION FACTOR; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 77954142914     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181d712ef     Document Type: Article

References (29)

1. Dressler GR, Douglass EC. Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilms tumor. Proc Natl Acad Sci. 1992;89:1179-1183.
2. Dressler GR, Wilkinson JE, Rothenpieler UW, et al. Deregulation of Pax-2 expression in transgenic mice generates severe kidney abnormalities. Nature. 1993;362:65-67.
3. Maulbecker CC, Gruss P. The oncogenic potential of Pax genes. EMBO J. 1993;12:2361-2367.
4. Torres M, Gomex-Pardo E, Dressler GR et al. Pax-2 controls multiple steps of urogenital development. Development. 1995;121: 4057-4065.
5. Mansouri A, Hallonet M, Gruss P. Pax genes and their roles in cell differentiation and development. Curr Opin Cell Biol. 1996;8: 851-857.
6. Stuart ET, Gruss P. PAX. Developmental control genes in cell growth and differentiation. Cell Growth Differ. 1996;7:405-412. (Pubitemid 26360779)
7. Dahl E, Koseki H, Balling R. Pax genes and organogenesis. Bioassays. 1997;9:755-765.
8. Eccles MR. The role of Pax-2 in normal and abnormal development of the urinary tract. Pediatr Nephrol. 1998;12:712-720.
9. Dressler GR, Woolf AS. Pax2 in development and renal disease. Int J Dev Biol. 1999;43:463-468.
10. Kuure S, Vuolteenaho R, Vainio S. Kidney morphogenesis: cellular and molecular regulation. Mech Dev. 2000;92:31-45.
11. Ozcan A, Zhai J, Candice H, et al. PAX-2 in the diagnosis of primary renal tumors: immunohistochemical comparison with the renal cell carcinoma marker antigen and kidney-specific cadherin. Am J Clin Pathol. 2009;131:393-404.
12. Daniel L, Lechevallier E, Giorgi R, et al. Pax-2 expression in adult renal tumors. Hum Pathol. 2001;32:282-287.
13. Tong GX, Melamed J, Mansukhani M, et al. PAX2: a reliable marker for nephrogenic adenoma. Mod Pathol. 2006;19:356-363.
14. Tong GX, Chiriboga L, Hamele-Bena D, et al. Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Mullerian system origin? Mod Pathol. 2007;20:856-863.
15. Eccles MR, He S, Legge M, et al. PAX genes in development and disease: the role of PAX2 in urogenital tract development. Int J Dev Biol. 2002;46:535-544.
16. Bouchard M, Souabni A, Mandler M, et al. Nephric lineage specification by Pax2 and Pax8. Genes Dev. 2002;16:2958-2970.
17. Gupta S, Verfaillie C, Chmielewski D, et al. Isolation and characterization of kidney-derived stem cells. J Am Soc Nephrol. 2006;17: 3028-3040.
18. Loverre A, Capobiancol C, Pasquale Ditonno P, et al. Increase of proliferating renal progenitor cells in acute tubular necrosis underlying delayed graft function. Transplantation. 2008;85: 1112-1119.
19. Bussolati B, Bruno S, Grange C, et al. Isolation of renal progenitor cells from adult human kidney. Am J Pathol. 2005;166:545-555.
20. Amalinei C. Morphogenesis and differentiation of the female genital tract. Genetic determinism and epithelium-stromal interactions. Rev Med Chir Soc Med Nat Iasi. 2007;111:200-209.
21. Bartol FF, Wiley AA, Bagnell CA. Uterine development and endometrial programming. Soc Reprod Fert Suppl. 2006;62:113-130.
22. Khoor A, Whitsett JA, Stahlman MT, et al. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol. 1999;30:695-700.
23. Rothenberg EV, Pant R. Origins of lymphocyte developmental programs: transcription factor evidence. Semin Immunol. 2004;16: 227-238.
24. Gokden N, Gokden M, Phan DC, et al. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker. Am J Surg Pathol. 2008;32: 1462-1467.
25. Ingelfinger JR. Nephrogenic adenoma as renal tubular outposts. N Engl J Med. 2002;347:684-686.
26. Mazal PR, Schaufler R, Altenhuber-Muller R. Derivation of nephrogenic adenoma from renal tubular cells in kidney transplant recipients. N Engl J Med. 2002;347:653-659.
27. Silberstein GB, Dressler GR, Van Horn K. Expression of the PAX2 oncogene in human breast cancer and its role in progesterone-dependent mammary growth. Oncogene. 2002;21:1009-1016.
28. Khoubehi B, Kessling AM, Adshead JM, et al. Expression of the developmental and oncogenic PAX2 gene in human prostate cancer. J Urol. 2001;165:2115-2120.
29. McGregor DK, Khurana KK, Cao C, et al. Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody "Renal Cell Carcinoma Marker". Am J Surg Pathol. 2001;25: 1485-1492.